EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD ‐1 antibody for BRAF ‐mutated melanoma

Kenta Nakamura iD, Tomonori Yaguchi, Masashi Murata, Yosuke Ota, Asuka Mikoshiba, Yukiko Kiniwa, Ryuhei Okuyama, Yutaka Kawakami

Cancer Science · 2024

DOI: 10.1111/cas.16251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Kenta Nakamura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cellular Signaling, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Melanoma, Vemurafenib, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, Japan Agency for Medical Research and Development (AMED), Project for Cancer Research and Therapeutic Evolution (P-CREATE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programmed death 1 (PD‐1)/programmed death‐ligand 1 inhibitors are commonly used to treat various cancers, including melanoma. However, their efficacy as monotherapy is limited, and combination immunotherapies are being explored to improve outcomes. In this study, we investigated a combination immunotherapy involving an anti‐PD‐1 antibody that blocks the major adaptive immune‐resistant mechanisms, a BRAF inhibitor that inhibits melanoma cell proliferation, and multiple primary immune‐resistant mechanisms, such as cancer cell‐derived immunosuppressive cytokines, and a Toll‐like receptor 7 agonist that enhances innate immune responses that promote antitumor T‐cell induction and functions. Using a xenogeneic nude mouse model implanted with human BRAF ‐mutated melanoma, a BRAF inhibitor vemurafenib was found to restore T‐cell‐stimulatory activity in conventional dendritic cells by reducing immunosuppressive cytokines, including interleukin 6, produced by human melanoma. Additionally, intravenous administration of the Toll‐like receptor 7 agonist DSR6434 enhanced tumor growth inhibition by vemurafenib through stimulating the plasmacytoid dendritic cells/interferon‐α/natural killer cell pathways and augmenting the T‐cell‐stimulatory activity of conventional dendritic cells. In a syngeneic mouse model implanted with murine BRAF ‐mutated melanoma, the vemurafenib and DSR6434 combination synergistically augmented the induction of melanoma antigen gp100‐specific T cells and inhibited tumor growth. Notably, only triplet therapy with vemurafenib, DSR6434, and the anti‐PD‐1 antibody resulted in complete regression of SIY antigen‐transduced BRAF ‐mutated melanoma in a CD8 T‐cell‐dependent manner. These findings indicate that a triple‐combination strategy targeting adaptive and primary resistant mechanisms while enhancing innate immune responses that promote tumor‐specific T cells may be crucial for effective tumor eradication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafMelanomaVemurafenibProgrammed Cell Death 1 ReceptorToll-Like Receptor 7AnimalsHumansMiceCell Line, TumorMice, NudeDendritic CellsAntineoplastic Combined Chemotherapy ProtocolsXenograft Model Antitumor AssaysMutationFemaleImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

BRAFToll‐like receptor 7immune checkpoint inhibitorsmelanomaprogrammed death 1

Substanzen

Proto-Oncogene Proteins B-rafVemurafenibProgrammed Cell Death 1 ReceptorBRAF protein, humanToll-Like Receptor 7TLR7 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Division of Cellular Signaling, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan.
  • Department of Dermatology, Shinshu University School of Medicine, Nagano, Japan.
  • Department of Immunology and Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Cancer Research Unit, Sumitomo Pharma Co. Ltd., Osaka, Japan.
  • Department of Immunology, School of Medicine, International University of Health and Welfare, Chiba, Japan.

ORCID-Profile: Kenta Nakamura

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan
  • Japan Agency for Medical Research and Development (AMED)
  • Project for Cancer Research and Therapeutic Evolution (P-CREATE)
  • Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT)
  • Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Nakamura, K., Yaguchi, T., Murata, M., Ota, Y., Mikoshiba, A., Kiniwa, Y., Okuyama, R., & Kawakami, Y. (2024). Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD ‐1 antibody for BRAF ‐mutated melanoma. Cancer Science. https://doi.org/10.1111/cas.16251

Vancouver

Nakamura K, Yaguchi T, Murata M, Ota Y, Mikoshiba A, Kiniwa Y, et al. Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD ‐1 antibody for BRAF ‐mutated melanoma. Cancer Science. 2024. doi:10.1111/cas.16251

BibTeX
@article{Nakamura2024,
  author = {Nakamura, Kenta and Yaguchi, Tomonori and Murata, Masashi and Ota, Yosuke and Mikoshiba, Asuka and Kiniwa, Yukiko and Okuyama, Ryuhei and Kawakami, Yutaka},
  title = {Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD ‐1 antibody for BRAF ‐mutated melanoma},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16251}
}
Kostenlos starten →